Ampa One is FDA-cleared for treatment-resistant depression in adults.
Public source
Publisher name
Public post
Our co-founder Dr. Jonathan Downar sat down with HCPLive to discuss how TMS sessions have gone from 38 minutes to three, what that means for patient access, and where th…
Company
Ampa
TMS therapy that's portable and lightweight — no dedicated room, no upfront cost.
- Industry
- Technology, Information and Internet
- Location
- Palo Alto, US
- Company size
- 11–50 employees
About Ampa
Democratizing access to the next generation of mental & neurological health treatments.
See moreLatest activity
Latest activity from Ampa
5 signals
Customers & Market
Ampa is bringing TMS to Warsaw with Viking Psychiatry & Wellness and Sean Goddard and his team.
People
Ampa welcomed Nadine Malek Sarraf as the first Head of Marketing, marking the next phase of the company's work.
Legal & Regulatory
Ampa One is FDA-cleared for treatment-resistant depression in adults.
Discover more
Similar signals
Similar public activity from other companies.
Legal & Regulatory
Wave Neuroscience
Wave Neuroscience built MeRT® to treat PTSD symptoms and was cleared by the FDA for the treatment of PTSD.
Products & Services
Flow Neuroscience
Flow Neuroscience announced that Flow is now available by prescription across the United States for adults with moderate to severe Major Depressive Disorder using the Flow FL-100 at-home tDCS device.
Research & Knowledge
BrainsWay
BrainsWay published new peer-reviewed data showing that the percentage of patients with Major Depressive Disorder experiencing suicidal ideation decreased from 22.5% at baseline to 6.7% after six weeks of BrainsWay Deep TMS treatment in a secondary analysis of a multisite randomized trial.
Research & Knowledge
Magstim
Magstim published a randomized clinical trial published in JAMA Network Open exploring whether weekly maintenance transcranial magnetic stimulation (TMS) could help sustain improvement after a successful initial course.
Research & Knowledge
Relief Mental Health